Literature DB >> 33433245

Association of tuberculosis in patients with chronic myeloid leukemia: a treatment proposal based on literature review.

Phool Iqbal1, Ashraf Soliman2,3, Vincenzo De Sanctis4, Mohamed A Yassin5.   

Abstract

Introduction: Chronic Myeloid leukemia (CML) is one of the first hematological malignancy linked with genetic alterations and have a targeted therapy with Tyrosine Kinase Inhibitors. However, there are certain unanswered questions and many unmet needs which limit its treatment. Concurrent Mycobacterium Tuberculosis (Mtb) infection is one of those significant factors. Tuberculosis (TB) is a highly prevalent disease in association with diabetes mellitus, malignancy, poor socioeconomic environment, HIV, and other immunosuppressive conditions in developed and developing countries. Anti-TB medications can affect other drug's pharmacokinetics by altering liver enzymes metabolism and poses treatment challenge with CML medications.Areas covered: The authors performed a rigorous literature review between 2000 and 2020 using PubMed and Google Scholar, with the main focus on all articles addressing the topic of TB in CML. Authors highlighted the need to improve clinical diagnosis and to define management strategy for this dilemma.Expert opinion: In the current era, there are no clear guidelines or recommendations in the literature that address this problem. The aim of this review was to collect and carefully analyze the literature to highlight the need for comprehensive guidelines and propose an algorithm for better management of TB in patients with CML.

Entities:  

Keywords:  Chronic myeloid leukemia (CML); anti- TB medications; mycobacterium tuberculosis; treatment; tuberculosis (TB); tyrosine kinase inhibitors (TKI)

Mesh:

Substances:

Year:  2021        PMID: 33433245     DOI: 10.1080/17474086.2021.1875818

Source DB:  PubMed          Journal:  Expert Rev Hematol        ISSN: 1747-4094            Impact factor:   2.929


  8 in total

1.  Clinicopathological Variables and Outcome in Chronic Myeloid Leukemia Associated With BCR-ABL1 Transcript Type and Body Weight: An Outcome of European LeukemiaNet Project.

Authors:  Mohammad A J Abdulla; Prem Chandra; Susanna El Akiki; Mahmood B Aldapt; Sundus Sardar; Ammar Chapra; Abdulqadir J Nashwan; Claudio Sorio; Luisa Tomasello; Christian Boni; Mohamed A Yassin
Journal:  Cancer Control       Date:  2021 Jan-Dec       Impact factor: 3.302

2.  Coexistence of Prefibrotic Myelofibrosis with Monoclonal Gammopathy of Undetermined Significance: A Case Report.

Authors:  Omar M Ismail; Aliaa Amer; Feryal A Ibrahim; Mohammad Abu-Tineh; Mohamed A Yassin
Journal:  Case Rep Oncol       Date:  2021-10-14

3.  Dasatinib-Induced Colitis with Rectal Sparing in a Patient with Chronic Myeloid Leukemia (Chronic Phase) on Dasatinib as an Upfront Therapy: Case Report.

Authors:  Zakaria Maat; Kamran Mushtaq; Mohamed A Yassin
Journal:  Case Rep Oncol       Date:  2021-10-18

4.  Myasthenia Gravis and Myeloproliferative Neoplasms - Mere Association or Paraneoplastic Neurologic Syndrome: A Mini-Review.

Authors:  Sreethish Sasi; Mouhand Mohamed; P Chitrambika; Mohamed Yassin
Journal:  Acta Biomed       Date:  2022-01-19

5.  Osteolytic bone lesions in patients with primary myelofibrosis: A systematic review.

Authors:  Naim Battukh; Elrazi Ali; Mohamed Yassin
Journal:  Acta Biomed       Date:  2022-01-19

6.  SARS-CoV-2 Omicron Variant in Patients With Chronic Myeloid Leukemia: A Retrospective Study.

Authors:  Elrazi A Ali; Ibrahim Khamees; Mohammad Abu-Tineh; Hana Qasim; Awni Alshurafa; Khalid Ahmed; Lujain Malkawi; Mohamed A Yassin
Journal:  Cureus       Date:  2022-04-05

7.  Avascular necrosis in patients with chronic myeloid leukemia: A systematic review.

Authors:  Mohamed Yassin; Abdulrahman F Al-Mashdali; Husam N Al-Dubai
Journal:  Acta Biomed       Date:  2022-03-14

8.  The Impact of a Knowledge Discovery-Based Psychoanalytic Intervention in the Treatment of Tuberculosis in University Students with Different Doses of Isoniazid.

Authors:  Zhihui Xia; Youping Tan; Yumei Yang
Journal:  J Healthc Eng       Date:  2022-03-21       Impact factor: 2.682

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.